tradingkey.logo

Biotech firm MannKind's Q2 revenue rises 6%

ReutersAug 6, 2025 11:33 AM


Overview

  • MannKind Q2 2025 rev grows 6% yr/yr, driven by higher royalties and Afrezza demand

  • Company reports net income of $0.7 mln, reversing a loss from prior year

  • Co submits sBLA for Afrezza in pediatric population, advancing pipeline trials


Outlook

  • Company expects MNKD-201 Phase 2 trial initiation by year-end 2025

  • MannKind anticipates MNKD-101 interim enrollment target by early 4Q 2025

  • Company awaits Afrezza pediatric sBLA review decision in early 4Q 2025


Result Drivers

  • ROYALTIES BOOST - Revenue growth driven by increased royalties from Tyvaso DPI

  • AFREZZA DEMAND - Higher demand and pricing for Afrezza contributed to revenue increase

  • COLLABORATION REVENUE DECLINE - Decrease in collaboration revenue due to one-time items


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Net Income

$668,000

Q2 Basic EPS

Q2 Operating Income

$5.30 mln

Q2 Pretax Profit

$940,000


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for MannKind Corp is $9.00, about 55.7% above its August 5 closing price of $3.99

  • The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nGNX5mCnsl

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI